Drug Approval | March 25, 2022
Japan approves BMS’ Breyanzi application for relapsed large B-cell lymphoma
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The expansion makes Exothera one of the largest viral vector facilities in Europe
Blood contains a mixture of exosomes secreted from nearly all tissues and cells, and exosomes from other tissues can mask changes caused by disease, making it difficult to detect the presence of biomarkers that reflect disease
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Machine learning approach to systems biology combined with ligand discovery platform
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
Subscribe To Our Newsletter & Stay Updated
